about
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.Upcoming translational challenges for uveal melanomaTargeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenograftsPhase-II trials in osteosarcoma recurrences: A systematic review of past experience.Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.Results of 32 allograft-prosthesis composite reconstructions of the proximal femurGenome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma.Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.The off-label use of targeted therapies in sarcomas: the OUTC'S programSorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenografts.Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage.Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.SF3B1 mutations are associated with alternative splicing in uveal melanoma.Therapeutic options in metastatic uveal melanoma.Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.Patient-derived xenografts recapitulate molecular features of human uveal melanomas.Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma.Protein Tyrosine Phosphatase 4A3 (PTP4A3) Promotes Human Uveal Melanoma Aggressiveness Through Membrane Accumulation of Matrix Metalloproteinase 14 (MMP14).Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics.Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases.
P50
Q24812405-C871534C-F165-4BA7-B378-17C1AA13202FQ26778535-40E31331-490D-4E0C-8080-AC89272AAE88Q28538631-66CD522B-0D24-4E3E-8E96-97D9EA95E5C3Q30235839-E636822A-4402-4164-98AD-7DC8F9604844Q31018689-E54E13AD-F141-42B9-AA2E-1EF9B605785DQ33370331-7B4E6803-31A8-41D5-B704-3A27F95F426AQ33381250-51894C47-3741-425E-A490-AFFB739A203BQ33421348-23FA9424-6C91-4654-9A5E-FEEDAD362BA9Q33631297-D71F5317-828B-436F-8330-3088C734566EQ33659480-44423845-B16C-441D-BE23-6FFAD41B0083Q33805555-92F3179A-F7BE-490F-8248-84ED166F99F1Q34897996-F4B3A93A-47BD-43CA-8995-3635B894E30DQ35776264-E5D82089-B337-4E6F-B9BC-F37F94D613C8Q36264686-122FC2A0-B022-467B-87D7-EAB75701DB6CQ36549378-E0227D25-4D24-483A-B7F4-E31992A553ACQ36673510-5414C122-D6B1-4B45-83A9-3BCE64BACF36Q37660348-12218FBC-E6C2-48F6-A31F-97F4508E9111Q37951351-83398596-069C-4326-986A-4B40288FFF5FQ38186853-5169BB7E-09F1-435F-8084-14F5216583F9Q38317188-E1408B9B-7A13-4C70-99C5-808EA408B403Q38374773-E935AB89-94BD-408F-B9E7-8DDA04D179CBQ38395321-43F881A1-34C0-41C3-8EB4-C9114C106645Q38776846-9D030E1F-86AB-43EB-97C7-C752347F7E3FQ38870980-4E209190-9C4F-4DD2-893C-86B8E2D8AFFDQ38978135-F6D83A63-400D-4ADC-8BB5-CC3754C3E814Q38983361-CEC9E197-34D0-4541-8982-AEFBCA9B37CCQ39483197-93257D3B-39DA-4103-ABD7-225700338637Q40009512-4DC71266-7FFA-4613-9EC2-5C636F4581BD
P50
description
onderzoeker
@nl
name
Sophie Piperno-Neumann
@ast
Sophie Piperno-Neumann
@en
Sophie Piperno-Neumann
@es
Sophie Piperno-Neumann
@sl
type
label
Sophie Piperno-Neumann
@ast
Sophie Piperno-Neumann
@en
Sophie Piperno-Neumann
@es
Sophie Piperno-Neumann
@sl
prefLabel
Sophie Piperno-Neumann
@ast
Sophie Piperno-Neumann
@en
Sophie Piperno-Neumann
@es
Sophie Piperno-Neumann
@sl